Some people who stutter have higher levels of dopamine in their brains than people who don't, and researchers say medications that boost dopamine—such as ADHD stimulants—may worsen stuttering.

Many people with ADHD are prescribed stimulant medication to assist with symptoms ranging from time blindness to executive dysfunction. This hour-long podcast episode by Search Engine explores the host's experience with ADHD medication and the history of amphetamine and methylphenidate use in the US.

LSD, psilocybin, and MDMA can suppress the brain's default mode network and enhance connectivity. Research shows that, when paired with therapy, psychedelics may help treat mental health conditions, including depression, addiction, and PTSD.

Though other antipsychotics block dopamine receptors, a new drug, Cobenfy, influences dopamine levels via a different pathway—it stimulates a pair of specialized receptors in the brain that control the release of a substance called acetylcholine. This alternative approach may help patients avoid serious side effects like weight gain.

Scientists are investigating psilocybin, ketamine, LSD, and MDMA (also known as ecstasy) as potential treatments for mental health issues. These drugs enable an altered state of consciousness, which can have beneficial or harmful impacts depending on the nature of the experience. Research suggests these drugs can be effective in treating substance use disorders, mental health conditions, including depression and anxiety, and psychiatric disorders, including schizophrenia.

Animal studies involving microdoses of psilocybin, the psychoactive component in magic mushrooms and ketamine, found it helped to alleviate anxiety and inflammation, an immune response that can cause damage when chronically active. Human studies are ongoing. In at least one double-blind study, where researchers and patients don't know who got a placebo versus the real thing, about half of the participants incorrectly guessed they had been given placebos.

LSD and psilocybin have shown promise as antidepressants. Using a virtual library of similar chemical compounds, researchers determined via animal studies that two molecules inspired by LSD have antidepressant effects without any associated hallucinogenic experience. These molecules were found to be 40 times more potent than the common antidepressant fluoxetine, also known as Prozac, with antidepressant effects lasting up to 21 days.

Brain imaging shows that ayahuasca, MDMA, DMT, and psilocybin profoundly affect neural activity, giving rise to higher states of introspection and consciousness. This article details exactly how each of these drugs physically affects the brain and what that means for mental health treatment. Some of these drugs quiet the brain or trigger the release of neurochemicals associated with mood regulation and learning.

Many such compounds (including LSD, psilocybin, and more) are classified as Schedule I drugs—illegal to possess and federally regarded as having no medical use. Researchers say such restrictions have created significant hurdles for formal clinical trials. With this executive order, the FDA will enable work particularly focused on depression, PTSD, and alcohol use disorder.

Critics argue that deep brain stimulation should be considered a last resort and not a scalable solution, given its high costs and trials limited to small samples. However, it has helped some patients manage severe opioid use disorder when conventional methods didn’t work.

After decades of repression, psychedelic research is making a resurgence. Hear from a host of experts in this 20-minute video on what that could mean for the future of mental health. The current science on psychedelics believes LSD can cause a particular brain network to quiet or deactivate.

DBS is a surgical procedure that uses implanted electrodes to send electrical signals to targeted areas in the brain, interrupting abnormal neural activity. It may be implemented when medications lose effectiveness or cause disruptive side effects.

Addictive substances or behaviors will typically flood our brains with more dopamine than usual. In response to the overstimulation, our brains will decrease the number of available dopamine receptors. This results in the need for more stimulus for the same response (tolerance) and a rise in negative feelings when the stimulus is absent (withdrawal).

Proponents say this short-acting psychedelic, formally known as dimethyltryptamine, could be particularly promising for medicinal use because longer-acting psychedelics can sideline someone for hours after a treatment with hallucinations. DMT is the primary psychoactive ingredient in ayahuasca, a psychoactive brew used across various South American cultures for spiritual, social, and medicinal purposes.

This article explores whether the therapeutic potential of psychedelic drug use is really as good as current research suggests. Scientists are exploring its applications for conditions ranging from the existential crisis that can accompany terminal diagnoses to chronic mental health conditions, including anxiety and PTSD.

Up to 80% of schizophrenia patients may have auditory hallucinations. Recent research concluded that this symptom may be from misfired motor signals that feed into each other, essentially failing to suppress certain sensory neural activities and that resulting overexcitment fuels hallucinations. The finding suggests that, one day, magnetic pulses might be used to stimulate specific nerves to better regulate the errant signals and reduce or stop hallucinations.

This video explores similarities and differences between these two disorders, which both have genetic causes. Challenges with attention, hyperactivity, and impulsivity are typical of ADHD. Fidgeting, problems picking up on social cues, emotional dysregulation, and being oblivious to time may occur with both disorders—though the impetus for these behaviors may differ.

Neuroscientist Judy Grisel breaks down the biology of addiction, examining how drugs hijack the brain’s natural reward system and create lasting neural changes. The physiological and neurological impacts of chronic drug use require a multifaceted treatment approach.

How magical are magic mushrooms, at least where depression is concerned? Some 24 volunteers participated in a study to evaluate the efficacy of using psilocybin in combination with psychotherapy to treat individuals suffering from depression. While some controversies remain about its use—psilocybin is known to cause psychosis sometimes—some scientists think the benefits outweigh the risks.

Certain gene variants can affect how quickly or slowly medications are broken down in the body, affecting drug effectiveness and the risk of drugs failing. Such testing is often not covered by insurance companies though research indicates if these tests were performed for more than six drugs across the US population, avoided ailments would likely climb into the hundreds of thousands.

Although the substance is banned in the US, it's legal in Mexico. Americans who have traveled there for treatment, including the NFL's Braden Smith, say the drug helps deal with conditions like obsessive-compulsive disorder.

The country green lighted the treatments for July 1, 2023, onward, with MDMA—ectasy—as a post-traumatic stress disorder treatment, and psilocybin—magic mushrooms—as an option for people with treatment-resistant depression.

Individuals with this mental health condition are routinely eliminated from any psychedelic research due to concerns about triggering or worsening psychosis. Yet there is little high-quality research in this area, raising questions about if further research into this question is warranted as interest grows in using psychedelics for therapeutic purposes.

While ADHD is most often recognized for producing struggles with attention and organization, these executive functions are critical for capturing the data that creates memories in the brain. Breaking data into pieces, or chunking, helps address these struggles.

Treatment for depression has historically hinged on the theory that the condition was caused by underactive or abnormal neurotransmitters, specifically serotonin and norepinephrine. This four-minute video by Yale Medicine details how these neurotransmitters didn't explain the symptoms of depression but, two other neurotransmitters involved in regulating mood and emotion did. GABA and glutamate, some of the brain's most plentiful neurotransmitters, may possibly be the source of depressive symptoms.

The nature of consciousness—what it is, where it comes from, and how it manifests as moment-to-moment experience—remains under debate by scientists. Recent studies show psychedelics were found to boost low-frequency brain signals known as delta waves, a behavior also seen during dream states.

Research shows that psychedelics may induce something called "critical periods" in the adult brain, which can make our brains more open to learning and changing, like they once were back in early childhood. Psychedelics similarly change how social creatures like octopuses behave, which demonstrates that these animals could help us better understand our own neurobiology.

Individual environment and life experiences affect how genes perform in the body, potentially adding methyl groups to DNA that affect their function and turning genes on and off—which may heighten or reduce disease risk.

Those with ADHD—chronic issues with attention and executive function—are primed for SAD. Many are disproportionately evening chronotypes (more awake in the evening), have a delayed sleep phase, and have low sensitivity to light in the morning. This podcast explores the overlap between these two groups.

Burnout isn't just a feeling—it physically affects the brain. Prolonged stress impairs regions of the brain responsible for decision-making, emotional control, memory, and more. It can also lead to chemical imbalances, like reduced dopamine and norepinephrine levels, that worsen these effects.

In this video, Michael Pollan, author of "This Is Your Mind On Plants," underscores the gaps in existing understanding about the substances and recommends only taking guided experiences, for safety and help. He tackles how psychedelics work, explains microdosing and psychedelic risks, how the substances could be used to treat addiction, and the history of psychedelic stigma.

Differences in the type of fame, such as movie stardom, sports, and internet virality, can produce varying degrees of dependence on individuals based on their age and background. Some individuals—particularly children—can develop drug-seeking behavior as they pursue continuous dopamine spikes if they lack an existing sense of fulfillment from elsewhere.

Studies indicate 75% of people with substance use disorder have experienced at least one traumatic experience in their life. These experiences alter brain function, leading to heightened stress and emotional pain. Substances offer temporary relief, but this often results in dependency.

Normal pleasure circuits become overwhelmed by addictive substances, triggering dopamine floods many times stronger than those induced by everyday reward experiences. The understanding of addiction as a brain disease has led to treatments pairing medication and counseling.

Researchers have determined that LSD, taken in a medical setting, decreases anxiety related to "life-threatening disease," reduces brain reactivity to fearful faces, increases the meaning and emotional response derived from music, and more. No complications of LSD administration have been observed in medical settings, though acute adverse effects, including exhaustion, nausea, and difficulty concentrating.

This compound, which is illegal to use in the US, has had promising results for patients who have tried it in other countries for substance abuse and mental health concerns. This psychoactive substance is not without risks, however; this TED talk points out it's also caused fatal cardiac arrhythmias and shouldn't be taken without medical supervision.

The decision was considered to be a major setback for moving psychedelics into the mainstream for mental health treatment. Pharmaceutical company Lykos, who had applied for the approval, had already attracted significant support from patients, politicians on both sides of the aisle, and leaders in the mental health field.

A 2006 study into the potential therapeutic benefits of psychedelics sparked a renewed interest in the field of psychedelic research, a development that has cascaded into commercialized ventures and experiences. This article details how growing research into the psychological benefits of psychedelics is matched by the rise of anecdotal reports, book deals, businesses, and corporate claims seeking to capitalize on psychedelic potential.